NCT02572843 - Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 16, 2016

Primary Completion Date

January 20, 2020

Study Completion Date

March 19, 2024

Conditions

NSCLC Non-small Cell Lung Cancer

Interventions

DRUG

MEDI4736 (anti-PD-L1)

fixed dosing 750 mg

Trial Locations (19)

1004

CCAC Lausanne, Lausanne

1708

Hopital Fribourgeois HFR, Fribourg

3600

Regionalspital, Thun

4016

St. Claraspital Basel, Basel

4031

Universitaetsspital Basel, Basel

5404

Kantonsspital Baden, Baden

6500

IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona

8063

Stadtspital Triemli, Zurich

9007

Kantonsspital St. Gallen, Sankt Gallen

CH-5001

Kantonsspital Aarau, Aarau

CH-3010

Inselspital Bern, Bern

CH-7000

Kantonsspital Graubuenden, Chur

CH-8500

Spital Thurgau AG, Frauenfeld

CH-1211

Hopital Cantonal Universitaire de Geneve, Geneva

CH-1011

Centre hospitalier universitaire vaudois CHUV, Lausanne

CH-6000

Luzerner Kantonsspital, Lucerne

CH-8401

Kantonsspital Winterthur, Winterthur

CH-8032

Klinik Hirslanden Onkozentrum Zürich, Zurich

CH-8091

UniversitaetsSpital Zuerich, Zurich

All Listed Sponsors

lead

Swiss Cancer Institute

OTHER